Compare · JNJ vs PRFX
JNJ vs PRFX
Side-by-side comparison of Johnson & Johnson (JNJ) and PRF Technologies Ltd. (PRFX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and PRFX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $655.56B, about 248122.1x PRFX ($2.6M).
- Over the past year, JNJ is up 45.7% and PRFX is down 86.0% - JNJ leads by 131.7 points.
- JNJ has been more active in the news (17 items in the past 4 weeks vs 6 for PRFX).
- JNJ has more recent analyst coverage (25 ratings vs 0 for PRFX).
- Company
- Johnson & Johnson
- PRF Technologies Ltd.
- Price
- $272.45-1.41%
- $0.75+2.60%
- Market cap
- $655.56B
- $2.6M
- 1M return
- +5.40%
- -22.72%
- 1Y return
- +45.73%
- -85.96%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 17
- 6
- Recent ratings
- 25
- 0
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
PRF Technologies Ltd.
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
Latest JNJ
- Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
- Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
- Johnson & Johnson to Host Enterprise Business Review
- SEC Form 13F-HR filed by Johnson & Johnson
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
- Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
- Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
- Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026
- SEC Form 10-Q filed by Johnson & Johnson
- Johnson & Johnson downgraded by Erste Group
Latest PRFX
- SEC Form 6-K filed by PRF Technologies Ltd.
- SEC Form 6-K filed by PRF Technologies Ltd.
- PRF Technologies and Dotz Nano Sign Term Sheet for Strategic Collaboration to Expand AI-Driven Energy Optimization Offering
- Amendment: SEC Form SCHEDULE 13D/A filed by PRF Technologies Ltd.
- SEC Form 6-K filed by PRF Technologies Ltd.
- PRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing™-K and GridFeed™ Opportunity in AI Data Center Power
- SEC Form 6-K filed by PRF Technologies Ltd.
- SEC Form 6-K filed by PRF Technologies Ltd.
- PRF Technologies’ GridFeed(TM) to Explore Strategic Growth Opportunity in AI Data Center Power Optimization
- SEC Form 6-K filed by PRF Technologies Ltd.